Funding for this research was provided by:
Kræftens Bekæmpelse (R90-A6143-14-S2, R149-A10159-B120)
Text and Data Mining valid from 2020-01-08
Received: 26 July 2019
Accepted: 31 December 2019
First Online: 8 January 2020
Compliance with ethical standards
: Morten Orebo Holmström, Mads Hald Andersen, and Hans Carl Hasselbalch have filed a patent regarding <i>CALR</i> exon 9 mutations as targets for cancer immune therapy. The patent has been transferred to Zealand University Hospital, Zealand Region and to Herlev Hospital, Capital Region, Denmark, according to Danish Law concerning inventions created at public research institutions. The authors declare that there are no other conflicts of interest.
: All projects described herein were approved by the local Ethics Committee in Zealand Region, Denmark, with the approval numbers: SJ-456, SJ-585, SJ-114, SJ-113, and SJ-452.
: All patients and healthy donors provided both written and oral informed consent on the use of their biological material for research and for publication. The consent was received before the sampling of biological material from the individual.